Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
Systematic review and meta-analysis of observational studies was conducted in PubMed, Embase, and Web of Science from 2006 to 2025. 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included. When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62-1.64; I2, 89%), glaucoma (HR, 0.84; 95% CI, 0.71-1.00; I2, 91%), and retinopathy (HR, 0.96; 95% CI, 0.85-1.08). Even if no difference was observed, it is optimal to monitor the administration of these molecules.
Overview
CoChat Summary
## TL;DR
This systematic review and meta-analysis of 28 observational studies found no statistically significant increase in ocular adverse events with GLP-1 receptor agonists versus other antidiabetic drugs for NAION, glaucoma, or diabetic retinopathy. The authors still recommend monitoring, because the evidence showed high heterogeneity and some outcomes were driven by only a few studies.
## Key findings
- The review included 28 observational studies: 6 single-arm studies and 22 double-/three-arm studies, all in T2DM patients.
- In the overall analysis, GLP-1 RAs did not increase risk of NAION: RR 1.01 (95% CI 0.62–1.64; I² = 89%).
- GLP-1 RAs did not increase risk of glaucoma relative to non-GLP-1 comparators: HR 0.84 (95% CI 0.71–1.00; I² = 91%).
- GLP-1 RAs did not increase risk of new-onset diabetic retinopathy: HR 0.96 (95% CI 0.85–1.08; I² = 91%), and did not increase risk of retinopathy progression: HR 0.97 (95% CI 0.83–1.14; I² = 65%).
- In single-arm studies, the pooled prevalence of ocular adverse events was 2% (95% CI 0.01–0.03), and the pooled prevalence of diabetic retinopathy was 4% (95% CI 0.01–0.08).
## Methods
- Design: PRISMA-guided systematic review and random-effects meta-analysis of observational studies, registered in PROSPERO (CRD420251080120).
- Data/sample: Searches of PubMed, Embase, and Web of Science from 1 January 2006 to 7 March 2025 identified 5,713 articles; 28 observational studies met inclusion criteria. Included populations had T2DM and/or overweight/obesity and used GLP-1 RAs such as semaglutide, dulaglutide, liraglutide, lixisenatide, exenatide, or tirzepatide.
- Main analysis: Random-effects meta-analysis of ocular outcomes (NAION, glaucoma, new-onset DR, DR progression); heterogeneity was assessed with Q and I², publication bias with funnel plots when possible, and leave-one-out sensitivity analyses were performed.
## Limitations
- The paper explicitly states that the meta-analysis is limited by substantial heterogeneity, different study characteristics (sample size, geography, follow-up), limited subgroup data, and possible confounding from concomitant antidiabetic therapies.
- The paper also states that many studies lacked detailed clinical/biochemical data or disease severity information, and that some outcomes, especially NAION, were based on few studies, making estimates less robust.
- Evident from the text: because nearly all included studies were observational and many were retrospective, the results are vulnerable to confounding and selection bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
1 Valid · 0 Not valid · 2 Not checked · 20 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62–1.64; I2, 89%)”
- Also stated in: § Double-arm studies comparing semaglutide vs. non-GLP-1 RAs · plain
“The results of the analysis stratified by the diabetic population did not show a statistically significant increased risk of developing NAION in the semaglutide group compared to that with other treatments (RR: 1.01; 95% CI: 0.62–1.64)”
- Also stated in: § Discussion · plain
“Literature data evaluated in our meta-analysis, most of which were related to semaglutide, did not show an increased risk of developing NAION in the semaglutide group compared to that in other GLP-1 RAs (RR: 1.01; IC 0.62–1.64).”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing semaglutide vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“retinopathy (new onset or progression) [(HR, 0.96; 95% CI, 0.85–1.08; I2, 91%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“Combining the results from all these studies, no statistically significant differences between the groups were found in terms of new-onset of DR (HR: 0.96; 95% CI: 0.85–1.08), with very high heterogeneity among the studies (I2, 91%; p < 0.001)”
- Also stated in: § Discussion · plain
“our results showed a slightly not statistically significant increased risk of developing new-onset DR or DR in the non-GLP-1 group (HR, 0.96; 95% CI: 0.85–1.08”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“glaucoma (HR, 0.84; 95% CI, 0.71–1.00; I2, 91%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“The overall risk showed a statistically increased risk of developing glaucoma in the non-GLP-1 RAs group (HR: 0.84; 95% CI: 0.71–1.00) with high heterogeneity (I2, 91%; p < 0.001)”
- Also stated in: § Discussion · hedged
“In line with their results, an increased risk of developing glaucoma in the non-GLP-1 RAs group was detected (HR: 0.84; 95% CI: 0.71–1.00), even if it was not statistically significant”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(HR, 0.97; 95% CI, 0.83–1.14; I2, 65%)”
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
“Overall, no statistically significant differences between the groups (HR: 0.97; 95% CI: 0.83–1.14) were found; heterogeneity among the studies was moderate (I2, 65%; p < 0.001)”
- Also stated in: § Discussion · hedged
“our results showed a slightly not statistically significant increased risk of developing new-onset DR or DR in the non-GLP-1 group (HR, 0.96; 95% CI: 0.85–1.08; HR, 0.97; 95% CI: 0.83–1.14).”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Double-arm studies comparing GLP-1 RAs vs. non-GLP-1 RAs · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included.”
- Also stated in: § Studies’ characteristics · plain
“A total of 5,713 articles were identified from the three databases (Figure 1). After the removal of duplicates (n = 2,176) and following full-text screening, 28 observational studies met the inclusion criteria and were included in the review”
§ Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Studies’ characteristics · plain
6 more claims
Create a free account to see all 23 claims and every source verdict.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 5
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“…risk of developing DR in some clinical studies, such as the SUSTAIN 6 cardiovascular outcome trial, which compared semaglutide to placebo (HR, 1.76; 95% CI, 1.11–2.78) (Marso et al., 2016a) and the LEADER cardiovascular outcome trial which compared liraglutide to placebo (Marso et al., 2016b).”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“…risk of developing DR in some clinical studies, such as the SUSTAIN 6 cardiovascular outcome trial, which compared semaglutide to placebo (HR, 1.76; 95% CI, 1.11–2.78) (Marso et al., 2016a) and the LEADER cardiovascular outcome trial which compared liraglutide to placebo (Marso et al., 2016b).”
InfluentialThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779 · cited 1×
“…further sensitivity analyses; however, the limited number of studies and data presented for each outcome advisable, considering, for example, the duration of diabetes, the treatment duration with GLP-1 Ras, and the influence of previously concomitantly received medications (Sterne and Egger, 2001).”
Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
Lo, C. K.-L., Mertz, D., & Loeb, M. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-45 · Cited by 2,477 · cited 3×
“Regarding the study design, 27 of them were cohort studies [three prospective (Grauslund et al., 2026; Lo et al., 2014; Caballero Mateo et al., 2024), 23 retrospective (Chou et al., 2024; Simonsen et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Douros et al.,…”
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“…in blood glucose levels and glycated hemoglobin, increase in insulin secretion in hyperglycemic conditions, inhibition of glucagon release, protection of β -cell function, improvement of cardio-renal function, and inhibition of gastric emptying (Movahednasab et al., 2025; Nauck et al., 2021).”
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358 · cited 1×
“Inflammation is involved in the pathophysiology of DR as well (Wang and Lo, 2018).”
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“Injection-site reactions, headache, and nasopharyngitis are other common non-serious and reversible AEs (Wojtara et al., 2023; An et al., 2025; Filippatos et al., 2014; Davies et al., 2022).”
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446 · cited 1×
“If PDR is not treated, it can turn into visual impairment with retinal detachment (Zheng et al., 2023; Hui et al., 2024; Lin et al., 2021).”
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · cited 1×
“…in the presence of at least one weight-related comorbid condition (Ruggiero et al., 2024; Cimmaruta et al., 2016; Liu, 2024; Mariam and Niazi, 2024; European Medicines Agency EMA, 2025a; European Medicines Agency EMa, 2025b; European Medicines Agency EMA, 2025c; Drucker, 2024; Trujillo, 2020).”
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318 · cited 6×
“…(Chou et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Kick et al., 2024; Lin et al., 2023; Eleftheriadou et al., 2024; Wang et al., 2018; Lin et al., 2024; Hathaway et al., 2024; Cai et al., 2025; Allan et al., 2025; Muayad et al., 2025; Sterling et al., 2023).”
InfluentialMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265 · cited 1×
“…and obesity or overweight patients in the presence of at least one weight-related comorbid condition (Ruggiero et al., 2024; Cimmaruta et al., 2016; Liu, 2024; Mariam and Niazi, 2024; European Medicines Agency EMA, 2025a; European Medicines Agency EMa, 2025b; European Medicines Agency EMA, 2025c;…”
A Brief History of the Development of Diabetes Medications
White, J. R. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.82 · Cited by 177 · cited 1×
“Even if the “incretin effect” is a long-known concept (White, 2014), the first GLP-1 RA, exenatide, was approved by the European Medicine Agency (EMA) only in 2006, followed by liraglutide (2009), lixisenatide (2013), dulaglutide (2014), semaglutide (2018), and the dual GIP and GLP-1 receptor…”
Biologic Risk Factors Associated with Diabetic Retinopathy
Varma, R., Macias, G. L., Torres, M., Klein, R., Peña, F. Y., & Azen, S. P. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.023 · Cited by 151
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
Trujillo, J. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13225 · Cited by 130 · cited 1×
“…in the presence of at least one weight-related comorbid condition (Ruggiero et al., 2024; Cimmaruta et al., 2016; Liu, 2024; Mariam and Niazi, 2024; European Medicines Agency EMA, 2025a; European Medicines Agency EMa, 2025b; European Medicines Agency EMA, 2025c; Drucker, 2024; Trujillo, 2020).”
Glucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, C. X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S. S., Flowers, A., Brown, E. N., Toy, B., Xu, B., Chen, J., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6555 · Cited by 129
Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Chou, C.-C., Pan, S.-Y., Sheen, Y.-J., Lin, J.-F., Lin, C.-H., Lin, H.-J., Wang, I.-J., & Weng, C.-H. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.10.030 · Cited by 104
Halim, M. A., Degerblad, M., Sundbom, M., Karlbom, U., Holst, J. J., Webb, D.-L., & Hellström, P. M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02006 · Cited by 102
(2024) · doi:10.1101/2024.12.09.24318574 · Cited by 85
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16316 · Cited by 85
GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials
Kapoor, I., Sarvepalli, S. M., D’Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.07.002 · Cited by 81 · cited 3×
“Similarly, the use of GLP-1 RAs was not associated with an increased risk of DR complications (RR, 1.10, 95% CI, 0.72–1.67; p, 0.67) compared to that with insulin or OAD (Kapoor et al., 2023).”
InfluentialGrauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00620-x · Cited by 79 · cited 8×
“In most studies (Grauslund et al., 2026; Simonsen et al., 2024; European Medicine Agency; Caballero Mateo et al., 2024; Mahzari et al., 2024; Albargawi et al., 2024; Kamin et al., 2021; Ueda et al., 2019; Tauqeer et al., 2025; Lin et al., 2024; Wang et al., 2018; Hasselstrøm Jensen et al., 2024;…”
InfluentialTang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13232 · Cited by 78 · cited 1×
“This is in line with the findings of the network meta-analysis of 37 RCTs carried out by Tang et al., showing that GLP-1 RAs and other antidiabetic drugs as DPP-4i and SGLT2-i are not associated with a higher risk of DR than placebo (OR, 1.19; 95% CI, 0.94–1.52) (Tang et al., 2018).”
InfluentialGlucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
Sterling, J., Hua, P., Dunaief, J. L., Cui, Q. N., & VanderBeek, B. L. (2023) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319232 · Cited by 75 · cited 6×
“…(Chou et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Kick et al., 2024; Lin et al., 2023; Eleftheriadou et al., 2024; Wang et al., 2018; Lin et al., 2024; Hathaway et al., 2024; Cai et al., 2025; Allan et al., 2025; Muayad et al., 2025; Sterling et al., 2023).”
InfluentialZheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02753-6 · Cited by 74 · cited 7×
“…2021; Albargawi et al., 2024; Mahzari et al., 2024; Caballero Mateo et al., 2024; Mayer and Fontelo, 2024; Kick et al., 2024; Douros et al., 2018; Zheng et al., 2023; Yen et al., 2024; Lin et al., 2023; Eleftheriadou et al., 2024; Hasselstrøm Jensen et al., 2024; Wang et al., 2018; Lin et al.,…”
InfluentialEleftheriadou, A., Riley, D., Zhao, S. S., Austin, P., Hernández, G., Lip, G. Y. H., Jackson, T. L., Wilding, J. P. H., & Alam, U. (2024) · Diabetologia · doi:10.1007/s00125-024-06132-5 · Cited by 73
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71 · cited 1×
“In particular, neuroprotection on the retina can be explained with different mechanisms involving the prevention of glutamate excitotoxicity, neuroinflammation, loss of retinal ganglion cells, vascular dysfunction, oxidative stress, and glial cell change (Mouhammad et al., 2022; Cui et al., 2022).”
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70
Current research and future strategies for the management of vision-threatening diabetic retinopathy
Li, H., Jia, W., Vujosevic, S., Sabanayagam, C., Grauslund, J., Sivaprasad, S., & Wong, T. Y. (2024) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2024.100109 · Cited by 59 · cited 1×
“One of the clinical signs of DR is diabetic macular edema (DME), which, together with vitreous hemorrhage or retinal detachment, can lead to blindness (Li et al., 2024).”
Ruggiero, R., Mascolo, A., Spezzaferri, A., Carpentieri, C., Torella, D., Sportiello, L., Rossi, F., Paolisso, G., & Capuano, A. (2024) · Pharmaceuticals · doi:10.3390/ph17020147 · Cited by 55
Self-citationAllan, K. C., Joo, J. H., Kim, S., Shaia, J., Kaelber, D. C., Singh, R., Talcott, K. E., & Rachitskaya, A. V. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.01.016 · Cited by 54
Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults
Wang, T., Hong, J.-L., Gower, E. W., Pate, V., Garg, S., Buse, J. B., & Stürmer, T. (2018) · Diabetes Care · doi:10.2337/dc17-2285 · Cited by 52
Rafaniello, C., Arcoraci, V., Ferrajolo, C., Sportiello, L., Sullo, M. G., Giorgianni, F., Trifirò, G., Tari, M. G., Caputi, A. P., Rossi, F., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.12.007 · Cited by 51 · cited 1×
“Indeed, patients suffering from diabetes commonly develop both macrovascular complications, including coronary heart disease, stroke, and peripheral arterial disease, and microvascular ones, such as peripheral neuropathy and retinopathy (Rafaniello et al., 2015).”
Self-citationSilverii, G. A., Pala, L., Cresci, B., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16076 · Cited by 49 · cited 1×
“This is in line with the results of a recent meta-analysis of RCTs, which demonstrated that GLP-1 RAs were not statistically associated with the risk of NAION (OR: 1.53; 95% CI: 0.53–4.44) ( Silverii et al., 2025).”
InfluentialKlonoff, D. C., Hui, G., & Gombar, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241268050 · Cited by 49 · cited 2×
“…indicating a possible risk of non-arteritic anterior ischemic optic neuropathy (NAION) after the administration of semaglutide (Chou et al., 2024; Klonoff et al., 2024; Grauslund et al., 2026; Simonsen et al., 2024), the EMA Pharmacovigilance Risk Assessment Committee (PRAC) started a review of…”
Niazi, S., Gnesin, F., Thein, A.-S., Andreasen, J. R., Horwitz, A., Mouhammad, Z. A., Jawad, B. N., Niazi, Z., Pourhadi, N., Zareini, B., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.03.004 · Cited by 47 · cited 6×
“Seven studies (Niazi et al., 2024; Shao et al., 2022; Allan et al., 2025; Muayad et al., 2025; Sterling et al., 2023; Chuang et al., 2024; Eng et al., 2025) reported on the occurrence of glaucoma by comparing GLP-1 RAs vs. non-GLP-1 RAs (other antidiabetic medications) in patients with T2DM.”
InfluentialMovahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 46 · cited 1×
“…in blood glucose levels and glycated hemoglobin, increase in insulin secretion in hyperglycemic conditions, inhibition of glucagon release, protection of β -cell function, improvement of cardio-renal function, and inhibition of gastric emptying (Movahednasab et al., 2025; Nauck et al., 2021).”
Muayad, J., Loya, A., Hussain, Z. S., Chauhan, M. Z., Alsoudi, A. F., De Francesco, T., & Ahmed, I. I. K. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.08.023 · Cited by 45 · cited 6×
“…(Chou et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Kick et al., 2024; Lin et al., 2023; Eleftheriadou et al., 2024; Wang et al., 2018; Lin et al., 2024; Hathaway et al., 2024; Cai et al., 2025; Allan et al., 2025; Muayad et al., 2025; Sterling et al., 2023).”
InfluentialLin, T.-Y., Kang, E. Y.-C., Shao, S.-C., Lai, E. C.-C., Garg, S. J., Chen, K.-J., Kang, J.-H., Wu, W.-C., Lai, C.-C., & Hwang, Y.-S. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0221 · Cited by 44 · cited 7×
“…et al., 2024; Albargawi et al., 2024; Mahzari et al., 2024; Mayer and Fontelo, 2024; Douros et al., 2018; Zheng et al., 2023; Yen et al., 2024; Lin et al., 2023; Eleftheriadou et al., 2024; Hasselstrøm Jensen et al., 2024; Wang et al., 2018; Lin et al., 2024; Tauqeer et al., 2025; Ueda et…”
InfluentialEffects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43 · cited 1×
“A helpful review by Ntentakis et al. indicates that even if PPAR-gamma agonists may worsen DME and semaglutide may slightly worsen DR, most classes of antidiabetic drugs are neutral to the progression of this microvascular disease (Ntentakis et al., 2024).”
Kick, A., M'Rabet‐Bensalah, K., Acquistapace, F., Amadid, H., Ambühl, R. A., Braae, U. C., Item, F., Schultes, B., Züger, T., & Rudofsky, G. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01525-y · Cited by 41 · cited 6×
“…et al., 2025; Muayad et al., 2025; Sterling et al., 2023; Chuang et al., 2024; Eng et al., 2025), one study reported data on the occurrence of retinal detachment (Kick et al., 2024), and another study reported vision impairment and disorder of the optic nerve as outcomes (Mayer and Fontelo, 2024).”
InfluentialShao, S.-C., Su, Y.-C., Lai, E. C.-C., Chang, K.-C., Lee, C.-N., Hung, M.-J., Lai, C.-C., Huang, F.-C., & Hung, J.-H. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101318 · Cited by 40 · cited 5×
“…Jensen et al., 2024; Wang et al., 2018; Lin et al., 2024; Tauqeer et al., 2025; Ueda et al., 2019; Hathaway et al., 2024; Cai et al., 2025; Shao et al., 2022; Allan et al., 2025; Muayad et al., 2025; Sterling et al., 2023; Chuang et al., 2024; Eng et al., 2025), and one ambispective…”
InfluentialGlucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 35 · cited 1×
“In particular, neuroprotection on the retina can be explained with different mechanisms involving the prevention of glutamate excitotoxicity, neuroinflammation, loss of retinal ganglion cells, vascular dysfunction, oxidative stress, and glial cell change (Mouhammad et al., 2022; Cui et al., 2022).”
Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist
Vasu, P., Dorairaj, E. A., Weinreb, R. N., Huang, A. S., & Dorairaj, S. K. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.02.011 · Cited by 34 · cited 1×
“A recent cohort study of Vasu et al. carried out among non-diabetic, obese, and/or overweight patients showed that the use of GLP-1 RAs was associated with a significantly lower risk of glaucoma and ocular hypertension compared with alternative weight-loss therapy (Vasu et al., 2025).”
Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
Self-citationGLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis
Amaral, D. C., Guedes, J., Cruz, M. M., Cheidde, L., Nepomuceno, M., Magalhães, P., Brazuna, R., Mora-Paez, D. J., Huang, P., Razeghinejad, R., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.024 · Cited by 32
Hallaj, S., Halfpenny, W., Chuter, B., Weinreb, R. N., Baxter, S. L., & Cui, Q. N. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.030 · Cited by 29
Nonlinear relationship between diabetes mellitus duration and diabetic retinopathy
Zhang, D., Zhang, Y., Kang, J., & Li, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-82068-5 · Cited by 28 · cited 1×
“Frontiers in Pharmacology frontiersin.org 13 Anatriello et al. 10.3389/fphar.2026.1808359 history, mainly due to prolonged exposure to hyperglycemia that leads to a higher risk of vascular damage (Zhang et al., 2024; Chaurasia et al., 2023; Varma et al., 2007).”
InfluentialAn, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25 · cited 1×
“Injection-site reactions, headache, and nasopharyngitis are other common non-serious and reversible AEs (Wojtara et al., 2023; An et al., 2025; Filippatos et al., 2014; Davies et al., 2022).”
Ueda, P., Pasternak, B., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., & Svanström, H. (2019) · Diabetes Care · doi:10.2337/dc18-2532 · Cited by 24
Advancement in Understanding Diabetic Retinopathy: A Comprehensive Review
Chaurasia, S., Thool, A. R., Ansari, K. K., & Saifi, A. I. (2023) · Cureus · doi:10.7759/cureus.49211 · Cited by 24 · cited 1×
“Frontiers in Pharmacology frontiersin.org 13 Anatriello et al. 10.3389/fphar.2026.1808359 history, mainly due to prolonged exposure to hyperglycemia that leads to a higher risk of vascular damage (Zhang et al., 2024; Chaurasia et al., 2023; Varma et al., 2007).”
InfluentialChuang, C., Wang, K., Chang, C., Lee, C., Huang, J., Wu, H., Yang, P., & Yang, S. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.90273 · Cited by 22
Ronsini, C., Pasanisi, F., Cianci, S., Vastarella, M. G., Pennacchio, M., Torella, M., Ercoli, A., & Colacurci, N. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2023.1180060 · Cited by 17
Glaucoma: Diagnosis and Management.
Michels, T. C., & Ivan, O. (2023) · PubMed · Cited by 17
Lin, D. S., Lo, H., Huang, K., Lin, T., Lee, J., & Lin, L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15788 · Cited by 16
Tauqeer, Z., Bracha, P., Hua, P., Yu, Y., Cui, Q. N., & VanderBeek, B. L. (2025) · Ophthalmic Epidemiology · doi:10.1080/09286586.2024.2399764 · Cited by 16
Balzano, N., Napoli, R. D., Fraenza, F., Cesare, D. D. G., Moreggia, O., Cardillo, M., Scavone, C., Maniscalco, G. T., Capuano, A., & Sportiello, L. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00725-6 · Cited by 15 · cited 1×
“…prospective studies and real-world active surveillance programs are required to better clarify the association between GLP-1 RAs and ocular adverse events and strengthen the current evidence base (Nicoletti et al., 2023; Mascolo et al., 2025; Balzano et al., 2025; Di Napoli et al., 2025).”
Self-citationGlucagon-like peptide-1 receptor agonists and the eye
Zhang, D. L., & Finn, A. P. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001137 · Cited by 15
Nicoletti, M. M., Anatriello, A., Liguori, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111611 · Cited by 14 · cited 1×
“…prospective studies and real-world active surveillance programs are required to better clarify the association between GLP-1 RAs and ocular adverse events and strengthen the current evidence base (Nicoletti et al., 2023; Mascolo et al., 2025; Balzano et al., 2025; Di Napoli et al., 2025).”
Self-citationJensen, J. H., Vestergaard, P., & Jensen, M. H. (2023) · Current Drug Safety · doi:10.2174/1574886318666230420084701 · Cited by 14
Eng, K., Zebardast, N., Boland, M. V., Lo, J., Swaminathan, S. S., Friedman, D. S., & Sheng‐Kai, K. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.029 · Cited by 13
Asif, M., Asif, A., Rahman, U. A., Farooqi, H. A., Fatima, O., Ali, W., Jafar, U., & Amin, M. H. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70059 · Cited by 13 · cited 2×
“…conducted by Amaral and Asif on the risk of glaucoma associated to GLP-1 RAs administration provide five comparisons each (Amaral et al., 2025; Asif et al., 2025), while our meta-analysis offers a total of eight comparisons throughout seven studies, considering that the study of Allan et al.…”
Yen, F.-S., Wei, J. C.-C., Shih, Y.-H., Hung, Y.-T., Hsu, T.-J., Hsu, C.-C., & Hwu, C.-M. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103099 · Cited by 13
Mayer, C. S., & Fontelo, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15911 · Cited by 12 · cited 7×
“Based on the quality assessment, 18 out of 28 studies were classified as being of good quality, achieving three or four stars for the selection domain, two stars for the comparability domain, and three stars for the outcome domain/exposure domain; four studies were classified as being of fair quality, achieving two st…”
InfluentialRonsini, C., Reino, A., Molitierno, R., Vastarella, M. G., Mantia, E. L., & FRANCISCIS, P. D. (2023) · Life · doi:10.3390/life13071429 · Cited by 11 · cited 1×
“The retrieved articles were evaluated for the quality of evidence by using the Newcastle-Ottawa Scale (NOS) (Lo et al., 2014; Ronsini et al., 2023b), the results of which were converted into the Agency for Healthcare Research and Quality (AHRQ) standards and reported as good, fair, and poor.”
Mouhammad, Z. A., Rombaut, A., García-Bermúdez, M. Y., Vohra, R., Tribble, J. R., Williams, P. A., & Kolko, M. (2025) · Molecular Brain · doi:10.1186/s13041-025-01224-8 · Cited by 9 · cited 1×
“…of neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, stroke, diabetic retinopathy, and ocular hypertension, GLP-1 RAs demonstrated an impact the central nervous system, showing anti-inflammatory and neuroprotective activity in the brain and retina (Mouhammad et al., 2025).”
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
Mascolo, A., Zinzi, A., Gaio, M., Ruggiero, D., Scavone, C., Rossi, F., & Capuano, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00668-4 · Cited by 7 · cited 1×
“…prospective studies and real-world active surveillance programs are required to better clarify the association between GLP-1 RAs and ocular adverse events and strengthen the current evidence base (Nicoletti et al., 2023; Mascolo et al., 2025; Balzano et al., 2025; Di Napoli et al., 2025).”
Self-citationHui, B. T. K., Yeong, J. L., Pető, T., & Willoughby, C. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171240 · Cited by 6
Retinopathy risk factors in patients with type 2 diabetes on liraglutide
Mahzari, M. M., Alanazy, A. M., Feroz, Z., Almani, K. M., Alghamdi, M. A., Almadani, A. S., Alzahrani, M. K., Alibrahim, A. R., & Badri, M. (2024) · Medicine · doi:10.1097/md.0000000000039026 · Cited by 5
Albargawi, M. S., Alharbi, R. N., Alajlani, M. A., Abdulaal, I., & Aldakhil, L. O. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00207-7 · Cited by 4
(2025) · doi:10.1007/s40264-025-01578-x · Cited by 2
Self-citationKamin, M., Khan, S., Raja, U. Y., Ishtiaq, O., Malik, A. A., Rehman, T., & Wahab, M. U. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_402_21 · Cited by 1 · cited 8×
“…domain, while the remaining six studies (Albargawi et al., 2024; Mahzari et al., 2024; Caballero Mateo et al., 2024; Mayer and Fontelo, 2024; Kamin et al., 2021; Kick et al., 2024) were classified as being of poor quality due to the absence of stars for the comparability domain…”
Influential
Research works printed but not linked: 5
- PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines ozempic, Rybelsus Wegovy
- Summary of Product Characteristics (Saxenda)
- Summary of Product Characteristics (Wegovy)
- Summary of Product Characteristics (Mounjaro)
- International Diabetes Federation. IDF Diabetes Atlas, 2021, IDF Diabetes Atlas
Cited by
Alabed, S. T., Thomas, A., Szirth, B. C., & Khouri, A. S. (2026) · Neuro-Ophthalmology · doi:10.1080/01658107.2026.2741570
Metadata
- Authors
- Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Liguori, Valerio
- Venue
- Frontiers in pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2026-06-02
- Volume
- 17
- Pages
- 1808359-1808359
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC13269103
- OpenAlex
- W7163212561
- Cited by
- 3
- References
- 73
- Citations by year
- 2026: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- GLP-1 receptor agonists, ocular adverse effects, retinopathy, glaucoma, nonarteritic anterior ischemic optic neuropathy, semaglutide, type 2 diabetes, drug safety, antidiabetic drugs, obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.